High urgency

Expansion of Buprenorphine Treatment via Telemedicine Encounter

Detected July 5, 2026 · in Telehealth Cross-State Licensing

DEA and HHS have expanded regulations to allow buprenorphine treatment via telemedicine without an in-person exam, reducing barriers for opioid use disorder treatment.

Aforeworn detected this change in the Telehealth Cross-State Licensing space on July 5, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Telehealth platforms, virtual specialty clinics, behavioral-health providers, e-prescribers should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately effective; review and implement changes within 30 days.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Telehealth Cross-State Licensing continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

Practitioners can now prescribe buprenorphine via telemedicine without a prior in-person evaluation, under certain conditions.

Who it affects

Telehealth platforms, virtual specialty clinics, behavioral-health providers, e-prescribers

What you must do

Update prescribing protocols to align with new telemedicine flexibilities and ensure compliance with state and federal requirements.

Deadline

Immediately effective; review and implement changes within 30 days.

Source: https://www.federalregister.gov/documents/2025/01/17/2025-01049/expansion-of-buprenorphine-treatment-via-telemedicine-encounter

Never miss a change like this again

Aforeworn watches Telehealth Cross-State Licensing around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Telehealth Cross-State Licensing